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Introduction: We attempted to assess the correlation between the 
Doppler mode image patterns during endobronchial ultrasound-
guided (EBUS) transbronchial needle aspiration and the expression 
of angiogenesis-related molecules within lymph nodes in patients 
with non–small-cell lung cancer.
Methods: Thirty-eight archived EBUS- transbronchial needle aspi-
ration samples of lymph nodes (27 metastatic and 11 nonmetastatic) 
in patients with non–small-cell lung cancer with Doppler mode ultra-
sound image were analyzed. The Doppler mode image of the vascu-
lature of the targeted lymph node was categorized into the following 
groups: normal blood flow, low blood flow (LBF), and high blood 
flow (HBF). Vascular index ratio (vascular area/lymph node area) of 
each metastatic lymph node was calculated. Total RNA and protein 
was extracted and analyzed for expression of HIF-1α, VEGF-A, and 
VEGF-C by quantitative RT-PCR and enzyme-linked immunosor-
bent assay.
Results: Within the 27 metastatic lymph nodes, eight were categorized 
into the LBF group and 19 into the HBF group. Vascular index ratio was 
significantly higher in HBF than LBF (p = 0.0003). mRNA expression 
of HIF-1α and VEGF-A was significantly higher in metastatic lymph 
nodes than in benign lymph nodes (p < 0.0001). Compared with LBF 
and HBF, HIF-1α mRNA expression was significantly higher in LBF 
(p = 0.01) and VEGF-C mRNA expression was significantly higher 
in HBF (p = 0.0315). There was no significant difference in protein 
expression by enzyme-linked immunosorbent assay analysis.
Conclusions: The vascularity of metastatic lymph nodes observed by 
EBUS correlates with the mRNA expression of HIF-1α and VEGF-C 
(not VEGF-A). This correlation is a clinical utility that needs to be 
evaluated further.
Key Words: Doppler mode imaging, Endobronchial ultrasound, 
Non–small-cell lung cancer, Lymph node metastasis, Tumor angio-
genesis and lymphangiogenesis.
(J Thorac Oncol. 2012;7: 1661–1667)
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a minimally invasive modal-
ity with a high diagnostic yield for mediastinal staging of 
non–small cell lung cancer (NSCLC).1–3 EBUS-TBNA is a 
biopsy procedure, but the EBUS ultrasound image itself may 
also be helpful for the prediction of lymph node metastasis.4 
Metastatic tumor affects the lymph node structure and vascu-
larity. We have previously reported a standard EBUS image 
classification system for lymph nodes.5 In addition, we have 
recently reported a standard EBUS Doppler mode vascular 
image classification system for lymph nodes.6 We have shown 
its usefulness in discriminating between metastatic or nonmet-
astatic lymph nodes during the EBUS procedure and, hence, 
the possibility of reducing unnecessary biopsies during medi-
astinal staging using EBUS-TBNA.
The vascular structure of a normal lymph node is dis-
torted by tumor infiltration and neovascularization is observed 
in these metastatic lymph nodes in breast cancer and laryn-
geal cancer.7,8 It is possible to observe these vascular changes 
by endoscopic or endobronchial ultrasound,6,9,10 and these 
Doppler mode ultrasound findings may be related to tumor 
progression and patient survival in metastatic melanoma.11 
The neovascularization of tumors is known to correlate with 
several angiogenesis-related molecules, such as vascular 
endothelial growth factors (VEGFs).12 Gene expression of 
VEGF is regulated by hypoxia inducible factor (HIF) and is 
affected by the hypoxic microenvironment of the tumor.13 It is 
has been previously reported that high blood flow imaged by 
color power Doppler flow is associated with elevated VEGF 
protein level and increased risk of lymph node metastasis and 
poorer prognosis in patients with breast cancer.14,15
The expression of angiogenesis-related biomarkers 
reflects particular microenvironmental aspects of tumor tissue 
such as tissue hypoxia. Indeed, tissue hypoxia is a predictive 
factor for tumor response to radiotherapy.16 In addition, 
mRNA expression of VEGF is known to be a prognostic 
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marker of NSCLC.17 If we could demonstrate a correlation 
between the expression of angiogenesis-related molecules and 
Doppler mode ultrasound image findings, we could predict 
the angiogenesis-related molecular biomarker levels of lung 
cancer cells within metastatic lymph node. This would aid 
selection of treatment and help predict prognosis. The aim of 
this study was to assess the correlation between endobronchial 
ultrasound Doppler mode image patterns of mediastinal and/
or hilar lymph nodes and the expression of angiogenesis-
related molecules including HIF-1α, VEGF-A, and VEGF-C.
PATIENTS AND METHODS
Study Subjects
Patients with diagnosed lung cancer who underwent 
EBUS-TBNA using universal endoscopic ultrasound scan-
ner (EU-ME1; Olympus, Tokyo, Japan) were retrospectively 
reviewed (from April 2009 to October 2009). The clinical 
lymph node samples obtained by EBUS-TBNA were archived 
with patients’ agreement and used for analysis. Patients who 
had any prior treatment were excluded from this study. The 
definition of each lymph node location is as stated by the 7th 
edition of the Tumor Node Metastasis classification for lung 
cancer.18 This research was approved by the ethics committee 
of Chiba Cancer Center (No. 20–21, No. 21–10, No. 21–52). 
Written consent was obtained from all patients. All samples 
were coded and managed independently.
Lymph Node Observation Using EBUS
EBUS procedures were performed on an outpatient 
basis in patients under conscious sedation (midazolam) with 
local anesthesia. The convex probe endobronchial ultrasound 
(BF-UC260FW; Olympus) equipped with a linear probe on its 
tip was used to perform EBUS-TBNA. The ultrasound image 
was processed in the universal endoscopic ultrasound scanner 
(EU-ME1) and a fixed frequency of 10-MHz observation mode 
used. Before Doppler mode observation, conventional B-mode 
observation was performed, and measurements made of the long 
and short axis of the lymph node. The Doppler mode image was 
captured as JPEG images while viewing the maximum diam-
eter of the lymph node. In addition, the Doppler mode image 
was recorded in digital video format videotape and the vascular 
findings reviewed by three different individuals (TN, TA, and 
KY) blinded to the results of EBUS-TBNA. The final character-
istics of the vascular findings for each lymph node were based 
on an agreement of at least two reviewers.6
EBUS Doppler Mode Image Characteristics  
of Lymph Nodes
EBUS procedures and Doppler mode image inter-
pretations were performed in the same fashion as previously 
described.6 The characters of the vascular structures within 
the lymph nodes were graded based on EBUS Power Doppler 
mode images classification system.6 This classification system 
showed high intraobserver and interobserver agreement, which 
was considered to be almost perfect agreement (the Cohen’s 
kappa value to assess the intraobserver variability was 0.830–
0.853 and the Fleiss’s kappa value of 3 interobserver variability 
was 0.83).6 In this study, grade 0 and I were categorized as nor-
mal flow, grade II was categorized as low blood flow (LBF), and 
grade III was categorized as high blood flow (HBF) (Fig. 1).
Quantification of Vascular Index
For the quantitative analysis of vascular area within 
lymph node, we defined the vascular index ratio (VIR) (vas-
cular percentage area) as vascular area (color pixel area) per 
lymph node area (gray pixel area) on EBUS Doppler mode 
image. The VIR was determined with ImageJ 1.4519 (National 
Institutes of Health, Bethesda, MD) using the following image-
processing steps (Fig. 2): (1) a binary image was created from 
the raw image, which is used for the determination of Doppler 
mode image classification; (2) a lymph node area was manu-
ally clipped as region of interest (ROI); (3) the vascular area 
that was visualized as color pixel area was determined with 
a certain threshold level (the same level for all sections); (4) 
ImageJ measure function was used to determine both, the area 
of ROI area (gray pixel) and vascular area (color pixel); (5) the 
percentage of vascular area on the ROI was calculated.
FIGURE 1.  Endobronchial ultrasound-
guided power Doppler mode images 
classification system. Grade 0: no 
blood flow or small amounts of flow, 
grade I: a few main vessels running 
toward the center of the lymph node 
from the hilum, grade II: a few punc-
tiforms or rod-shapes of flow signal, a 
few small vessels found as a long strip 
of a curve, grade III: rich flow, more 
than four vessels found with different 
diameters and twist or helical-flow 
signal. Grade 0 and I were categorized 
as normal blood flow, grade II was cat-
egorized as low blood flow,, and grade 
III was categorized as high blood flow.
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EBUS-TBNA Procedure, Sample Storage, 
Isolation of RNA and Protein
EBUS-TBNA was performed to the same targeted 
lymph node as observed by Doppler mode. The procedures 
of EBUS-TBNA were performed in the same fashion as 
previously described.20,21 Rapid onsite cytology was not 
performed; however, an independent pathologist reviewed 
all cases and pathologically confirmed the presence or 
absence of NSCLC cells in each specimen. The procedures 
of EBUS-TBNA, sample storage, and isolation of RNA and 
protein were performed in the same fashion as previously 
described.22,23
Quantitative Real-Time Reverse Transcription  
Polymerase Chain Reaction
QuantiTect Reverse Transcription Kit (QIAGEN Inc., 
Valencia, CA) was used for reverse transcription. Quantitative 
real-time RT-PCR was performed in a LightCycler 480 (Roche 
Applied Science, Indianapolis, IN) using a LightCycler 480 
SYBR Green I Master (Roche) in a total volume of 20 mL. 
The samples were analyzed in duplicates. Human β2 micro-
globulin was selected as a housekeeping gene, which was 
used for internal control of gene expression analysis. HIF-1α, 
VEGF-A, and VEGF-C were selected as an angiogenesis-
related genes in this study (Table 1).
Measurement of Protein Expression
Targeted protein levels in the sample were determined 
using enzyme-linked immunoassay kit (Surveyor IC, 
Quantikine Immunoassay; R&D systems, Minneapolis, MN). 
These protein levels were normalized using total protein 
content measured by the Bio-Rad Protein Assay (Bio-Rad 
Laboratories, Hercules, CA). Finally, the expression ratio 
of targeted protein (target protein level [pg/mL]/protein 
concentration [μg/μL]) was calculated and analyzed.
Data Analysis
Statistical comparisons were made using the Mann–
Whitney U test. General data analysis was conducted using 
JMP 8.0 (SAS Institute Inc., Cary, NC). All p values were 
based on a two-sided hypothesis, with p values less than 0.05 
considered to have statistical significance.
RESULTS
Patients and Analyzed Samples
Thirty-eight archived clinical EBUS-TBNA samples 
were analyzed. There were 27 metastatic lymph nodes (17 
adenocarcinoma, 6 squamous cell carcinoma, 4 poorly dif-
ferentiated NSCLC) and 11 nonmetastatic lymph nodes. The 
characteristics of the lymph nodes analyzed in this study are 
summarized in Table 2. All nonmetastatic lymph nodes were 
graded as normal flow (grade 0 or I). Within the 27 positive 
lymph nodes, eight were categorized as LBF (grade II) and 
19 were categorized as HBF (grade III). The size of sampled 
lymph nodes ranged from 6.9 mm to 33.4 mm on EBUS imag-
ing and was significantly larger in metastatic lymph nodes 
(p = 0.0252). Station #4R and #7 were most frequently sam-
pled in metastatic lymph nodes, and #11 was most frequently 
sampled in nonmetastatic lymph nodes. Twenty-five of 27 meta-
static lymph nodes (92.6%) showed standardized uptake value 
more than 2.5, which was considered as positive for malignancy 
by 18F-fluorodeoxy glucose-positron emission tomography.
VIR Analysis in Metastatic Lymph Node
The mean pixel values of the lymph node area, which 
were visualized as gray pixel, were 216.70 mm2 (range, 
148.74–299.59) in the LBF group and 187.06 mm2 (range, 
FIGURE 2. Quantification of vascular 
index using ImageJ. For the quantitative 
analysis of vascular area within lymph 
node, we defined the vascular index 
ratio (vascular percentage area) as vas-
cular area (color pixel area) per region 
of interest (lymph node area) on endo-
bronchial ultrasound-guided Doppler 
mode image. ROI, region of interest.
TABLE 1. The Sequences of Primers
B2M 5ʹ to 3ʹ
Forward GAGGCTATCCAGCGTACTCC
Reverse CAATGTCGGATGGATGAAAC
HIF1-α 5ʹ to 3ʹ
Forward GGCAGCAACGACACAGAAAC
Reverse TGATTGAGTGCAGGGTCAGC
VEGF-A 5ʹ to 3ʹ
Forward CTACTGCCATCCAATCGAGAC
Reverse AATCTGCATGGTGATGTTGG
VEGF-C 5ʹ to 3ʹ
Forward GCCAACCTCAACTCAAGGAC
Reverse CCCACATCTGTAGACGGACA
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76.41–342.19) in the HBF group. The mean pixel values of 
vascular area, which were visualized as color pixel, were 
5.34 mm2 (range, 2.26–10.50) in the LBF group and 13.44 mm2 
(range, 3.83–33.6) in the HBF group. VIR was significantly 
higher in the HBF group (7.26% [range, 2.40%–13.75%]) than 
in the LBF group (2.54% [range, 1.49%–5.52%]) (p = 0.0003).
RNA and Protein Extraction
Total RNA was successfully isolated in all 38 samples. 
The median amount of isolated RNA was 6.85 μg from the 
nonmetastatic lymph node (range, 2.27–16.42) and 15.17 
μg from the metastatic lymph node (range, 2.00–61.22). The 
mean ratio of absorptions at 260 versus 280 nm for the purity 
of RNA was 1.83.
Protein was also successfully isolated in all 38 samples. 
The median amount of isolated protein was 4.25 mg (range, 
2.18–6.65) from the nonmetastatic lymph node and 3.44 mg 
(range, 0.17–12.46) from the metastatic lymph node.
mRNA Expression Levels of Angiogenesis- 
Related Genes
Gene expression levels of HIF1-α, VEGF-A, and VEGF-C 
were quantifiable in all samples. The mRNA expression levels 
relative to human β2 microglobulin are shown in Table 3.
HIF1-α (p < 0.0001) and VEGF-A (p < 0.0001) mRNA 
were expressed significantly higher in the metastatic lymph 
node versus the nonmetastatic lymph node. There was no sig-
nificant difference for VEGF-C (p = 0.6756) between meta-
static and nonmetastatic lymph nodes (Fig. 3).
Within metastatic lymph nodes, there were significant 
differences for HIF1-α and VEGF-C mRNA expressions. 
HIF1-α had significantly higher expression in the LBF group 
(p = 0.01), and VEGF-C had significantly higher expression 
in the HBF group (p = 0.0315), vice versa. Interestingly, there 
was no significant difference for VEGF-A expression between 
the LBF and HBF groups (p = 0.5069) (Fig. 4).
Enzyme-Linked Immunoassay 
Protein expression levels of HIF1-α, VEGF-A 
(VEGF-A
165
), and VEGF-C were quantified. Three out of 38 
samples for VEGF-A (VEGF-A
165
) and one out of 38 samples 
for VEGF-C could not be measured because of low protein con-
centration. The protein expression ratios were shown in Table 4.
There was no significant difference in HIF1-α (p = 0.9743), 
VEGF-A (VEGF-A
165
) (p = 0.1386), and VEGF-C protein 
expression (p = 0.6522) between metastatic and nonmetastatic 
lymph nodes. Within metastatic lymph nodes, there were also 
no significant differences for HIF1-α (p = 0.3259), VEGF-A 
(VEGF-A
165
) (p = 0.2761), and VEGF-C (p = 0.1757) protein 
expression between the LBF and HBF groups.
DISCUSSION
We have recently reported that the Doppler mode 
vascular image finding classification system of lymph nodes 
during EBUS can be used to distinguish between metastatic 
and nonmetastatic lymph nodes in patients with lung cancer.6 
There were two subtypes within the group of metastatic 
lymph nodes, which again, could be classified by blood-
flow pattern: Grade II—LBF and Grade III—HBF.6 In this 
study, we examined the expression of angiogenesis-related 
molecules within lymph nodes and revealed a correlation 
between Doppler mode ultrasound findings and molecular 
TABLE 2.  Characteristics of Analyzed Lymph Nodes
Metastatic  
LN
Nonmetastatic 
LN p
n 27 11
Histology type of primary 
tumor
Adenocarcinoma 17 6
Squamous cell carcinoma 6 3
Poorly differentiated NSCLC 4 2
Sampled lymph node station
2R 3 0
4R 10 2
4L 2 1
7 9 3
11 3 5
Mean LN size of CT (short 
axis, range)
21.4 (10–37) 15.3 (10–39) 0.1315
Mean LN size of EBUS (short 
axis, range)
18.1 (8.3–33.4) 13.4 (6.9–25.4) 0.0252
Doppler grade
NBF (Grade 0–I) 0 11
LBF (Grade II) 8 0
HBF (Grade III) 19 0
LN, lymph node; NSCLC, non–small-cell lung cancer; NBF, normal blood flow; 
LBF, low blood flow; HBF, high blood flow.
TABLE 3.  mRNA Expression Levels Relative to B2M
Median mRNA Expression Levels Relative to B2M
HIF1-α VEGF-A VEGF-C
Nonmetastatic LN 0.68 (0.26–0.89) 0.03 (0.01–0.04) 0.08 (0.01–0.19)
Metastatic LN 1.91 (0.76–6.97) p < 0.0001 1.01 (0.03–19.4) p < 0.0001 0.07 (0.002–2.8) p = 0.6756
LBF group 2.39 (1.15–5.49) 1.15 (0.57-7.67) 0.03 (0.01–0.14)
HBF group 1.50 (0.76–6.97) p = 0.01 0.91 (0.03–19.4) p = 0.5069 0.10 (0.002–2.8) p = 0.0315
LN, lymph node; LBF, low blood flow; HBF, high blood flow.
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FIGURE 3. mRNA expression levels 
between nonmetastatic lymph nodes 
and metastatic lymph nodes. HIF1-α 
(p < 0.0001) and VEGF-A (p < 0.0001) 
mRNA were significantly more highly 
expressed in the metastatic lymph 
node than in the nonmetastatic lymph 
node. There was no significant differ-
ence for VEGF-C (p = 0.6756) between 
metastatic and nonmetastatic lymph 
nodes. LN, lymph node.
FIGURE 4. mRNA expression levels 
between the LBF group and the HBF 
group. Within metastatic lymph nodes, 
there were significant differences in 
HIF1-α and VEGF-C mRNA expressions. 
HIF1-α had significantly higher expres-
sion in the LBF group (p = 0.01), and 
VEGF-C had significant higher expres-
sion in the HBF group (p = 0.0315) 
and vice versa. However, there was 
no significant difference for VEGF-A 
between the LBF and HBF groups  
(p = 0.5069). LBF, low blood flow; HBF, 
high blood flow.
TABLE 4.  Protein Expression Ratios
Median Protein Expression Ratio (target protein/total protein)
HIF1-α VEGF-A (VEGF
165
) VEGF-C
Nonmetastatic LN 20.71 (11.37–97.56) 32.84 (3.39–92.25) 810.77 (147.40–3114.93)
Metastatic LN 20.92 (3.78–275.71) p = 0.9743 14.27 (0–290.65) p = 0.1386 711.75 (0–5526.22) p = 0.6522
LBF group 45.85 (3.78–275.71) 7.42 (0–290.65) 267.65 (0–5526.22)
HBF group 20.40 (11.68–140.82) p = 0.3259 14.80 (0–205.32) p = 0.2761 732.62 (134.78–4353.74) p = 0.1757
VEGF, vascular endothelial growth factor; HIF1, hypoxia inducible factor; LN, lymph node; LBF, low blood flow; HBF, high blood flow.
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markers. Metastatic lymph nodes had significantly higher 
expression of both HIF1-α and VEGF-A than nonmetastatic 
nodes did. Furthermore, HIF1-α mRNA had significantly 
higher expression in the LBF group, and VEGF-C mRNA 
had significantly higher expression in the HBF group. This 
result may suggest the higher mRNA expression of HIF1-α 
in the LBF group may be induced by tissue hypoxia caused 
by LBF, and the higher mRNA expression of VEGF-C in the 
HBF group may result from the HBF within metastatic lymph 
nodes. Another explanation could be HIF1-α is first generated 
in a hypoxic state of metastatic lymph nodes, which causes 
high expression of VEGF-A, then subsequently increases the 
expression of VEGF-C; this is then seen in HBF lymph nodes.
The molecular markers analyzed in this study (HIF1-α, 
VEGF-A, and VEGF-C) are recognized as correlating with tis-
sue oxygenation (hypoxia) and tumor angiogenesis. Hypoxia 
has been shown to be a major inducer of VEGF gene tran-
scription.24 VEGF-A is known as the major mediator of tumor 
angiogenesis. VEGF-A is highly expressed in most types of 
human cancer cells.24 VEGF-C plays a major role in tumor lym-
phangiogenesis and expresses with its receptor (R), VEGFR-3, 
in lymphatic endothelial cells.25 These biomarkers have been 
identified as predictive factors for the response to radiother-
apy and chemotherapy.16,26 In addition, the mRNA expression 
of VEGF is established as a prognostic marker of NSCLC.17 
Improvements in the tissue hypoxic microenvironment by 
drugs may lead to change in the expression of these molecules 
and enhance treatment efficacy.27–29 VEGF-C is known to be 
related to lymphangiogenesis, lymph node metastasis, and 
poor prognosis in patients with lung cancer.30–33 In addition, 
VEGF-C is known to be an important target molecule in the 
regulation of lymph node and distant metastasis of cancer.34
Recently, the VEGF pathway has been targeted in 
patients with advanced NSCLC, by using therapy using beva-
cizumab with significant improvement of progression-free 
survival and overall survival.35 Bevacizumab is a human-
ized monoclonal antibody that inhibits VEGF-A.36 In addi-
tion to this anti-VEGF antibody, VEGF receptor tyrosine 
kinase inhibitors, such as pazopanib, have been developed. 
Pazopanib is a multitargeted tyrosine kinase receptor inhibitor 
of VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth 
factor receptor-a/β, and c-kit (receptors). This drug has dem-
onstrated an 86% reduction in tumor volume when adminis-
tered as a short-term preoperative treatment in patients with 
early-stage NSCLC.37 As shown in this study, VEGF-C is 
also highly expressed in metastatic lymph nodes; therefore, 
multitargeted VEGFR tyrosine kinase inhibition may be more 
effective for the treatment of locally advanced NSCLC.
One potential limitation of our study is protein analy-
sis using EBUS-TBNA samples. As previously described, 
samples obtained by EBUS-TBNA consisted mainly of tumor 
cells, blood constituent, and a small amount of lymph node tis-
sue.38 Compared with the number of tumor cells, there was rel-
atively little representation of normal or reactive tissue within 
the samples. Therefore, EBUS-TBNA samples can easily be 
used for genetic analysis. However, one potential limiting fac-
tor to using enzyme-linked immunosorbent assay analysis for 
EBUS samples is the presence of blood. Blood contamination 
causes hemodilution, affecting the results of protein analysis 
and this effect is varied by the degree of blood contamination. 
The mean value of HIF1-α, VEGF-A, and VEGF-C protein 
is higher in the LBF group; however, there was no signifi-
cant difference even between metastatic and nonmetastatic 
lymph nodes. Another limitation of this study is also related 
to quantity and quality of samples obtained by this needle 
biopsy procedure. The core can be used for histological evalu-
ation; however, it is basically cytological material.39 It is hard 
to obtain structured tissue that can be used for microvascular 
and lymphatics density evaluation by immunohistochemistry. 
It is known that several kinds of cells can produce and release 
VEGFs, including tumor cells, macrophages and monocytes, 
and signaling to VEGFRs on endothelial cells that regulate 
neovascularization. It is also difficult to identify VEGFs pro-
ducing cells and endothelial cells within the EBUS-TBNA 
samples. Further investigation will be needed to confirm this 
result and may need to evaluate surgically resected specimens.
In conclusion, this study was based on a limited num-
ber of samples; we have, however, demonstrated a significant 
association between Doppler mode findings and angiogenesis-
related molecules. The Doppler mode image findings of lymph 
nodes may provide us with additional information regarding 
the tumor microenvironment within metastatic lymph nodes. 
To evaluate this relationship fully, a large number of case 
series needs to be assessed so that these findings can be vali-
dated and applied clinically.
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